Contract development and manufacturing organization Neuland Laboratories said its new commercial peptide facility at Bonthapally will begin operations in summer, with Module One providing thousands of liters of SPPS and LPPS capacity. The site is modular with plans for further capacity additions and aims to serve innovators facing constrained peptide and GLP‑1 manufacturing supply. Neuland reported early module commitments and a scaling plan that includes clinical through multi‑ton commercial volumes. The expansion targets rising demand for long peptides and complex APIs and could ease bottlenecks that have strained peptide supply chains for late‑stage programs.